

해외 바이오의약품 임상 현황 (2020.09.21 ~ 2020.09.27)

한국바이오의약품협회, 2020.9.29.
출처: ClinicalTrials.gov

○ 미국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04539236	Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients	Myelodysplastic Syndromes	Drug: Lenalidomide Drug: Luspatercept	Mikael Sekeres MD Case Comprehensive Cancer Center	Phase 1 Phase 2
NCT04521764	A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Invasive Breast Carcinoma Metastatic Breast Adenocarcinoma Prognostic Stage IV Breast Cancer AJCC v8 Recurrent Breast Carcinoma	Biological: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein	Mayo Clinic National Cancer Institute (NCI)	Phase 1
NCT04491955	Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers	Small Bowel Cancers Colorectal Cancers	Biological: CV301 Drug: MSB0011359C Drug: N-803 Drug: NHS-IL12	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2
NCT04339777	Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases	Lymphoproliferative Disorders Autoimmune Lymphoproliferative Immune System Diseases Common Variable Immunodeficiency Primary T-cell Immunodeficiency Disorders	Drug: Busulfan test dose Drug: Fludarabine Drug: Busulfan Drug: Alemtuzumab Radiation: Total body Irradiation Procedure: Allogeneic HSCT Drug: Tacrolimus (Tacro) Drug: Mycophenolate mofetil (MMF) Drug: Cyclophosphamide (Cytosan)	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2
NCT04404595	Claudin18.2 CAR-T (CT041) in Patients With Gastric or Pancreatic Cancer	Gastric Cancer Pancreatic Cancer	Biological: CT041	Carsgen Therapeutics, Ltd.	Phase 1
NCT04487080	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Amivantamab Drug: Osimertinib Drug: Lazertinib Drug: Placebo	Janssen Research & Development, LLC	Phase 3

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04487080	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Amivantamab Drug: Osimertinib Drug: Lazertinib Drug: Placebo	Janssen Research & Development, LLC	Phase 3

○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04487080	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Amivantamab Drug: Osimertinib Drug: Lazertinib Drug: Placebo	Janssen Research & Development, LLC	Phase 3

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04064242	Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	Pulmonary Sarcoidosis	Drug: CMK389 Drug: Placebo	Novartis Pharmaceuticals Novartis	Phase 2
NCT04487080	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Amivantamab Drug: Osimertinib Drug: Lazertinib Drug: Placebo	Janssen Research & Development, LLC	Phase 3
NCT04483739	Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)	Multiple Myeloma	Drug: Carfilzomib Lenalidomide Dexamethasone Drug: Isatuximab Carfilzomib Lenalidomide Dexamethasone	European Myeloma Network EMN Research Italy Sanofi Amgen	Phase 3

○ 중국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04566770	Phase IIb Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	COVID-19	Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo	CanSino Biologics Inc Beijing Institute of Biotechnology Jiangsu Province Centers for Disease Control and Prevention	Phase 2
NCT04564313	Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation	Hepatocellular Carcinoma Liver Transplantation	Drug: Camrelizumab treatment	Third Affiliated Hospital, Sun Yat-Sen University	Phase 1
NCT04562311	Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma	Bladder Cancer Stage IV	Drug: Chidamide with tislelizumab	Sun Yat-sen University	Phase 2
NCT04560127	Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer	Radioactive Iodine-refractory Differentiated Thyroid Cancer	Drug: Camrelizumab combination with Apatinib	Peking Union Medical College Hospital	Phase 2
NCT04550663	NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors	Solid Tumor Hepatocellular Carcinoma Colorectal Cancer Glioma	Drug: KD-025 CAR-T cells	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School KAEDI	Phase 1
NCT04487080	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Amivantamab Drug: Osimertinib Drug: Lazertinib Drug: Placebo	Janssen Research & Development, LLC	Phase 3

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04487080	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Amivantamab Drug: Osimertinib Drug: Lazertinib Drug: Placebo	Janssen Research & Development, LLC	Phase 3